CAM
AKTX

Cormorant Asset Management’s Akari Therapeutics AKTX Stock Holding History

Cormorant Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-36
Closed -$687K – 84
2015
Q3 		$687K Hold
36
– – 0.11% 77
2015
Q2 		$166K Hold
36
– – 0.02% 80
2015
Q1 		$218K Sell
36
-2
-5% -$50K 0.03% 70
2014
Q4 		$1.44M Buy
38
+7
+23% +$306K 0.22% 56
2014
Q3 		$1.49M Buy
31
+18
+138% +$839K 0.31% 54
2014
Q2 		$639K Hold
13
– – 0.17% 54
2014
Q1 		$668K Buy
+13
New +$735K 0.15% 46

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cormorant Asset Management's AKTX Position: Q4 2015 in Review

Cormorant Asset Management sold out of Akari Therapeutics (AKTX) in Q4 2015, closing a stake of 36 shares — an estimated $687K sold.

Cormorant Asset Management first reported a position in AKTX in Q1 2014 and held it in 7 quarters. The position peaked at $1.49M in Q3 2014. 19 funds tracked by Wall St. Rank hold AKTX as of Q4 2015.

  • Cormorant Asset Management reported no remaining Akari Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Cormorant Asset Management sold 36 Akari Therapeutics shares in Q4 2015, an estimated $687K.
  • Cormorant Asset Management first reported a position in Akari Therapeutics in Q1 2014 and held it in 7 quarters.
  • Cormorant Asset Management's Akari Therapeutics position peaked at $1.49M in Q3 2014.
  • 19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2015.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.